Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2021 - 2026)

Zentalis Pharmaceuticals has reported Accumulated Expenses over the past 6 years, most recently at $27.9 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 33.13% year-over-year to $27.9 million; the TTM value through Mar 2026 reached $27.9 million, down 33.13%, while the annual FY2025 figure was $29.4 million, 35.19% down from the prior year.
  • Accumulated Expenses for Q1 2026 was $27.9 million at Zentalis Pharmaceuticals, down from $29.4 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $54.4 million in Q4 2023 and troughed at $27.9 million in Q1 2026.
  • A 5-year average of $40.3 million and a median of $43.5 million in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 43.59% in 2023 and later plummeted 35.43% in 2025.
  • Year by year, Accumulated Expenses stood at $45.4 million in 2022, then rose by 19.91% to $54.4 million in 2023, then dropped by 16.81% to $45.3 million in 2024, then plummeted by 35.19% to $29.4 million in 2025, then decreased by 5.09% to $27.9 million in 2026.
  • Business Quant data shows Accumulated Expenses for ZNTL at $27.9 million in Q1 2026, $29.4 million in Q4 2025, and $30.1 million in Q3 2025.